Catalog Products » CD96/TACTILE[Biotin], His & Avi, Human
Manual
Manual
COAs

CD96/TACTILE[Biotin], His & Avi, Human

The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
$660.00
Z04076-100

Ask us a question
Product Introduction
Species Human
Protein Construction
CD96/TACTILE (Val22-Met503)
Accession # P40200-2		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 59.1 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 115-140 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

CD96/TACTILE[Biotin], His & Avi, Human

Immobilized Anti-CD96 Antibody at 1 μg/ml(100 μl/well) on the plate. Dose response curve for CD96/TACTILE[Biotin], His & Avi, Human, His Tag with the EC50 of 0.46 μg/ml determined by ELISA. »

CD96/TACTILE[Biotin], His & Avi, Human

CD96/TACTILE[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

<
>

Background
Target Background The receptors CD96 and TIGIT are expressed on the surface of T and natural killer (NK) cells, and recent studies suggest both play important inhibitory roles in immune function. CD96 has been shown to modulate immune cell activity in mice, with Cd96-/- mice displaying hypersensitive NK-cell responses to immune challenge and significant tumor resistance. The counterbalance between the putative inhibitory CD96 and TIGIT receptors and the activating receptor, CD226, offers unique strategies for immuno-oncology drug development.
Synonyms CD96 molecule; CD96; DKFZp667E2122; TACTILE
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.